These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25484068)

  • 1. Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.
    Kamath AV; Yip V; Gupta P; Boswell CA; Bumbaca D; Haughney P; Castro J; Tsai SP; Pacheco G; Ross S; Yan M; Damico-Beyer LA; Khawli L; Shen BQ
    MAbs; 2014; 6(6):1631-7. PubMed ID: 25484068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.
    Couch JA; Zhang G; Beyer JC; de Zafra CL; Gupta P; Kamath AV; Lewin-Koh N; Tarrant J; Allamneni KP; Cain G; Yee S; Ross S; Cook R; Tsai SP; Ruppel J; Ridgway JB; Paluch M; Hass PE; Franklin J; Yan M
    Clin Cancer Res; 2016 Mar; 22(6):1469-79. PubMed ID: 26589434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
    Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
    Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
    Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.
    Yip V; Palma E; Tesar DB; Mundo EE; Bumbaca D; Torres EK; Reyes NA; Shen BQ; Fielder PJ; Prabhu S; Khawli LA; Boswell CA
    MAbs; 2014; 6(3):689-96. PubMed ID: 24572100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
    Li Y; Hickson JA; Ambrosi DJ; Haasch DL; Foster-Duke KD; Eaton LJ; DiGiammarino EL; Panchal SC; Jiang F; Mudd SR; Zhang C; Akella SS; Gao W; Ralston SL; Naumovski L; Gu J; Morgan-Lappe SE
    Mol Cancer Ther; 2018 May; 17(5):1039-1050. PubMed ID: 29592882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.
    Milenic D; Garmestani K; Dadachova E; Chappell L; Albert P; Hill D; Schlom J; Brechbiel M
    Cancer Biother Radiopharm; 2004 Apr; 19(2):135-47. PubMed ID: 15186593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
    Buchsbaum DJ; Wahl RL; Glenn SD; Normolle DP; Kaminski MS
    Cancer Res; 1992 Feb; 52(3):637-42. PubMed ID: 1732052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.